Clinicians Pipeline overview

10 obesity medications to watch

Originally posted Apr 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 955 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

Receptor targets, development stages, and key readouts across the treatment pipeline.

After a fast start to 2026 in obesity medicine, the pipeline ahead looks even more interesting.

We have already seen more treatment options emerge, including the launch of oral Wegovy, Wegovy HD, and Foundayo. Now the next wave is shaping up to go even further beyond simple GLP-1 monotherapy.

I put this infographic together to highlight 10 pipeline medications worth watching. For each one, I included what phase it is currently in, the receptor targets involved, and a key clinical result from a recent trial. The goal is not to make perfect head-to-head comparisons across studies, but to give a snapshot of where obesity pharmacotherapy may be heading next.

Here are the 10 I featured:

• Novo Nordisk CagriSema
Amylin + GLP-1 combination with strong late-stage data and one of the closest programs to potential approval.
• Eli Lilly and Company Retatrutide
A triple agonist targeting GLP-1, GIP, and glucagon that has shown some of the most impressive weight loss data we have seen so far.
• Amgen MariTide
A unique approach combining GLP-1 agonism with GIP receptor antagonism, with the added appeal of monthly or less frequent dosing potential.
• Boehringer Ingelheim Survodutide
A GLP-1 and glucagon dual agonist that is especially interesting not only for weight loss, but also for its potential metabolic and liver-related benefits.
• Viking Therapeutics, Inc. VK2735
A GLP-1/GIP dual agonist with strong early data, and it is also notable that both oral and subcutaneous formulations are being developed.
• Kailera Therapeutics Ribupatide
Another GLP-1/GIP dual agonist with very impressive weight loss results and growing momentum. Kailera went public last week in one of biotech's biggest-ever IPOs.
• Novo Nordisk Amycretin
A GLP-1 and amylin-based approach that stands out for both its strong efficacy signal and the fact that oral and subcutaneous versions are in development.
• Zealand Pharma / Roche Petrelintide
An amylin analog that may be especially interesting from a tolerability standpoint and could become an important option either alone or in combinations.
• Structure Therapeutics Aleniglipron
A once-daily oral small-molecule GLP-1 candidate that highlights how important the pill-based obesity treatment race may become.
• Altimmune, Inc. Pemvidutide
A GLP-1/glucagon dual agonist that is worth watching not just for weight loss, but also for its broader cardiometabolic and liver-related potential.

Edit to add: Also worth noting is Pfizer’s PF-08653944, from Metsera, an ultra-long-acting GLP-1. Phase 2b data showed 12.3% placebo-adjusted weight loss at 28 weeks, with once-monthly dosing potential.

What I find most exciting is that this pipeline is becoming much more diverse. Some agents may push efficacy higher. Some may improve tolerability. Some may offer oral administration or less frequent dosing. Some may be especially useful for patients with steatohepatitis or other metabolic comorbidities.

It is a very exciting time in obesity medicine!

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

10 obesity medications to watch

Pinch to zoom on touch devices. Open full image ↗